2.15.22 | Policy
SWHR Statement on Dr. Robert Califf Appointment
SWHR released a statement following the Senate’s confirmation of Dr. Robert Califf to serve as the Commissioner of Food and Drugs, Food and Drug Administration.
7.14.20 | Policy
SWHR Applauds House Appropriations Committee for Advancing HHS Funding Increases
In the midst of the COVID-19 pandemic, the work of U.S. public health agencies is more important than ever. SWHR commends the House Appropriations Committee on its approval of a FY21 appropriations bill increasing funding for NIH to $47 billion.
6.5.20 | Policy
SWHR Stands With the Black Community Against Racial Injustice
The Society for Women’s Health Research stands with the Black community against racial injustice.
1.17.20 | Policy
SWHR Launches Search for CEO in 2020
SWHR CEO Amy M. Miller announces that she is leaving in 2020 and SWHR begins search for new leader.
10.3.18 | Research and Clinical Trials
SWHR Applauds Report Addressing Research Gaps on Safe, Effective Therapies for Pregnant and Lactating Women
The Society for Women’s Health Research commends the Task Force on Research Specific to Pregnant Women and Lactating Women for its comprehensive, evidence-based report with pragmatic recommendations for addressing critical knowledge gaps on safe and effective medication for pregnant and lactating women.
3.22.18 | Research and Clinical Trials
SWHR Applauds Congress for Supporting Funding for NIH Office of Research on Women’s Health
SWHR commends Congress for recognizing the valuable role of NIH's Office of Research on Women's Health in the FY18 spending bill by calling for funding that reflects the office's important mission.
8.21.17 | Research and Clinical Trials
SWHR Lauds Passage and Signage of FDA Reauthorization Act of 2017 into Law
SWHR congratulates the Congress and the President for approving the Food and Drug Administration (FDA) Reauthorization Act of 2017. By providing significant funding and important improvements to FDA's medical products review and approval process, this law will enable timely access to safe and effective medical innovations to millions of patients who need them.
5.26.17 | Research and Clinical Trials
SWHR Calls on Congress to Make Significant Improvements to President’s 2018 Budget Proposal
SWHR is deeply concerned and discouraged to see that the Administration has deprioritized research and development in the 2018 budget through substantial decreases for critical federal agencies, expressed Dr. Amy M. Miller, SWHR president and CEO.
5.10.17 | Research and Clinical Trials
SWHR Supports Dr. Scott Gottlieb’s Confirmation to Lead FDA
Distinguished physician and health policy expert, Dr. Scott Gottlieb, has been confirmed by the Senate as the next Food and Drug Administration (FDA) Commissioner. President Donald Trump nominated him in March 2017.
4.20.17 | Research and Clinical Trials
Administrations May Change, But the Scientific Mission Should Not
The scientific community will gather this Earth Day, April 22, to take a public stand “to defend the vital role science plays in health, safety, economies, and governments,” at a March for Science event taking place in more than 500 cities across the world.
